CTMX Stock Price, CytomX Therapeutics Inc Quote, Chart

Market Summary

USD1.89-0.11

Market Closed

-5.50%

CTMX Stock Price

View Fullscreen

CTMX RSI Chart

CTMX Valuation

Market Cap

128.0M

Price/Earnings (Trailing)

7.74

Price/Sales (Trailing)

1.07

EV/EBITDA

5.03

Price/Free Cashflow

-1.39

CTMX Price/Sales (Trailing)

CTMX Profitability

EBT Margin

15.31%

Return on Equity

-52.19%

Return on Assets

8.95%

Free Cashflow Yield

-72.14%

CTMX Fundamentals

CTMX Revenue

Revenue (TTM)

119.2M

Rev. Growth (Yr)

76.45%

Rev. Growth (Qtr)

55.83%

CTMX Earnings

Earnings (TTM)

16.5M

Earnings Growth (Yr)

516.52%

Earnings Growth (Qtr)

1.5K%

Breaking Down CTMX Revenue

Last 7 days

-4.5%

Last 30 days

7.4%

Last 90 days

28.6%

Trailing 12 Months

4.4%

How does CTMX drawdown profile look like?

CTMX Financial Health

Current Ratio

1.16

CTMX Investor Care

Shares Dilution (1Y)

2.26%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	119.2M	0	0	0
2023	67.6M	79.5M	94.7M	101.2M
2022	38.2M	42.2M	44.2M	53.2M
2021	29.7M	31.5M	33.3M	37.3M
2020	74.9M	72.9M	69.6M	68.4M
2019	74.8M	62.5M	60.7M	57.5M
2018	74.2M	86.7M	75.1M	59.5M
2017	24.5M	30.1M	50.8M	71.6M
2016	8.2M	9.2M	10.8M	15.0M
2015	6.2M	7.6M	7.6M	7.7M
2014	1.9M	3.0M	4.0M	5.1M
2013	0	0	0	888.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of CytomX Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 26, 2024	mccarthy sean a.	acquired	172,874	1.5749	109,768	ceo
Mar 19, 2024	rowland lloyd a	sold	-10,986	2.0855	-5,268	general counsel
Mar 19, 2024	landau jeffrey b	sold	-13,685	2.0855	-6,562	chief business officer
Mar 19, 2024	ogden christopher	sold	-6,196	2.0855	-2,971	svp, finance and accounting
Mar 19, 2024	mccarthy sean a.	sold	-42,175	2.0855	-20,223	ceo
Mar 19, 2024	belvin marcia	sold	-26,684	2.0855	-12,795	svp, chief scientific officer
Jan 18, 2024	chu yu-waye	acquired	-	-	26,250	chief medical officer
Jan 18, 2024	rowland lloyd a	acquired	-	-	25,000	general counsel
Jan 18, 2024	mccarthy sean a.	acquired	-	-	90,000	ceo
Jan 18, 2024	belvin marcia	acquired	-	-	26,250	svp, chief scientific officer

Which funds bought or sold CTMX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	528	355,251	400,571	-%
May 16, 2024	Tidal Investments LLC	reduced	-5.88	156,475	630,941	0.01%
May 15, 2024	Squarepoint Ops LLC	added	39.6	224,803	458,129	-%
May 15, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	new	-	4,360,000	4,360,000	0.01%
May 15, 2024	Schonfeld Strategic Advisors LLC	new	-	2,778,420	2,778,420	0.02%
May 15, 2024	Laurion Capital Management LP	reduced	-30.14	-29,650	1,665,930	0.01%
May 15, 2024	TWO SIGMA ADVISERS, LP	added	256	256,164	320,024	-%
May 15, 2024	Sio Capital Management, LLC	new	-	3,484,930	3,484,930	1.04%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	reduced	-1.53	3,908,500	14,061,000	1.46%
May 15, 2024	Brevan Howard Capital Management LP	new	-	39,362	39,362	-%

Are Funds Buying or Selling CTMX?

Are funds buying CTMX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CTMX

No. of Funds

Unveiling CytomX Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 13, 2024	cormorant asset management, lp	7.38%	5,750,000	SC 13G
Feb 14, 2024	biotechnology value fund l p	5.4%	3,651,391	SC 13G/A
Feb 14, 2024	tang capital partners lp	9.8%	6,550,000	SC 13G/A
Feb 13, 2024	vanguard group inc	7.32%	4,902,943	SC 13G/A
Feb 14, 2023	point72 asset management, l.p.	0%	0	SC 13G/A
Feb 14, 2023	rtw investments, lp	0%	0	SC 13G/A
Feb 14, 2023	tang capital partners lp	5.3%	3,510,445	SC 13G/A
Feb 09, 2023	vanguard group inc	6.94%	4,585,721	SC 13G/A
Jul 29, 2022	biotechnology value fund l p	5.4%	3,544,303	SC 13G/A
Jul 08, 2022	blackrock inc.	2.8%	1,826,591	SC 13G

Recent SEC filings of CytomX Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	8-K	Current Report
May 13, 2024	SC 13G	Major Ownership Report
May 08, 2024	10-Q	Quarterly Report

Peers (Alternatives to CytomX Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

CytomX Therapeutics Inc News

Latest updates

CytomX Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	55.8%	41,463,000	26,607,000	26,384,000	24,724,000	23,499,000	20,123,000	11,147,000	12,853,000	9,040,000	11,132,000	9,189,000	8,795,000	8,197,000	7,078,000	7,466,000	6,988,000	46,895,000	8,279,000	10,712,000	9,013,000	29,485,000
Operating Expenses	9.5%	29,806,000	27,213,000	23,261,000	28,072,000	29,152,000	29,631,500	40,857,000	42,907,000	41,102,000	46,035,000	40,228,000	35,493,000	31,598,000	31,152,000	32,683,000	32,746,000	52,386,000	45,658,000	36,430,000	40,246,000	46,050,000
S&GA Expenses	-100.0%	-	7,827,000	6,813,000	7,401,000	7,977,000	10,067,500	10,490,000	11,748,000	10,543,000	9,455,000	11,085,000	9,393,000	9,227,000	9,145,000	8,634,000	8,680,000	9,572,000	9,217,000	8,463,000	9,411,000	9,674,000
R&D Expenses	13.8%	22,052,000	19,386,000	16,448,000	20,671,000	21,175,000	19,564,000	30,367,000	31,159,000	30,559,000	36,580,000	29,143,000	26,100,000	22,371,000	22,007,000	24,049,000	24,066,000	42,814,000	36,441,000	27,967,000	30,835,000	36,376,000
EBITDA Margin	455.0%	0.15	-0.04	-0.33	-0.84	-0.99	-1.80	-2.75	-2.92	-3.16	-3.00	-3.04	-3.02	-3.15	-	-	-	-	-	-	-	-
Income Taxes	-95.4%	49,000	1,069,000	2,823,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-13,911,000	-421,000	-	-	-6,000
Earnings Before Taxes	626.1%	13,840,000	1,906,000	5,815,000	-	-3,311,000	-8,775,500	-29,064,000	-29,496,000	-31,981,000	-34,823,000	-30,982,000	-26,736,000	-23,328,000	-23,996,000	-25,032,000	-25,299,000	-4,404,000	-66,463,500	-23,699,000	-28,960,000	-14,130,000
EBT Margin	455.0%	0.15	-0.04	-0.37	-0.89	-1.04	-1.87	-2.84	-3.02	-3.26	-3.11	-3.16	-3.14	-3.28	-	-	-	-	-	-	-	-
Net Income	1547.7%	13,791,000	837,000	2,992,000	-1,087,000	-3,311,000	-8,775,500	-29,064,000	-29,496,000	-31,981,000	-34,823,000	-30,982,000	-26,736,000	-23,328,000	-23,996,000	-25,032,000	-25,299,000	9,507,000	-35,455,000	-23,699,000	-28,960,000	-14,124,000
Net Income Margin	2567.5%	0.14	-0.01	-0.11	-0.53	-1.04	-1.87	-2.84	-3.02	-3.26	-3.11	-3.16	-3.14	-3.28	-	-	-	-	-	-	-	-
Free Cashflow	-17.7%	-26,160,000	-22,229,000	-18,252,000	-25,695,000	9,301,000	-1,575,000	-34,255,000	-34,649,000	-42,049,000	-31,437,000	-29,968,000	-28,313,000	-30,922,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-8.5%	185	202	221	209	235	261	226	260	297	339	371	402	434	359	375	402	437	341	373	405	445
Current Assets	-8.6%	167	183	201	188	212	237	200	233	268	310	241	271	400	324	340	367	400	303	335	367	405
Cash Equivalents	110.7%	36.00	17.00	26.00	58.00	56.00	194	95.00	129	163	206	236	256	330	192	177	291	143	188	165	149	190
Net PPE	-9.9%	4.00	4.00	4.00	4.00	5.00	5.00	6.00	6.00	6.00	6.00	6.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-13.2%	216	249	272	294	321	347	307	315	327	340	341	344	353	366	327	344	367	290	290	304	322
Current Liabilities	-7.3%	145	156	147	141	151	153	124	95.00	87.00	78.00	68.00	60.00	65.00	68.00	102	99.00	106	86.00	76.00	79.00	96.00
Shareholder's Equity	33.2%	-31.68	-47.45	-	-	-86.64	-85.75	28.00	49.00	68.00	89.00	30.00	58.00	81.00	50.00	48.00	59.00	70.00	25.00	82.00	102	123
Retained Earnings	1.9%	-709	-723	-724	-727	-726	-722	-714	-685	-655	-623	-588	-557	-531	-507	-435	-420	-405	-442	-381	-358	-329
Additional Paid-In Capital	0.3%	678	676	673	642	640	637	634	632	627	623	619	616	612	500	484	480	474	468	464	459	452
Shares Outstanding	-100.0%	-	67.00	81.00	66.00	66.00	66.00	66.00	66.00	65.00	65.00	64.00	63.00	61.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	114	-	-	-	118	-	-	-	408	-	-	-	379	-	-	-	502	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-18.6%	-26,045	-21,963	-18,243	-25,178	9,349	-1,393	-33,845	-34,237	-41,313	-31,192	-29,700	-28,199	-29,940	-17,427	-24,678	97,101	-49,737	-29,479	-23,319	-48,653	-39,029
Share Based Compensation	-25.3%	1,907	2,552	1,226	2,371	2,409	2,570	2,695	4,490	3,370	3,544	3,164	3,425	3,034	3,419	3,841	3,513	4,013	4,111	4,343	5,454	5,192
Cashflow From Investing	248.9%	44,885	12,866	-42,938	26,040	-146,642	99,818	-410	-412	-736	-245	9,734	-46,012	59,012	19,455	-90,067	49,453	2,441	52,857	38,510	6,940	-18,606
Cashflow From Financing	-28.7%	174	244	29,669	317	-	190	-	451	7.00	683	104	691	108,735	13,021	167	1,548	2,157	401	63.00	698	465

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CTMX Income Statement

2024-03-31

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Revenues	$ 41,463	$ 23,499
Type of Revenue [Extensible List]	us-gaap:LicenseAndServiceMember	us-gaap:LicenseAndServiceMember
Operating expenses:
Research and development	$ 22,052	$ 21,175
General and administrative	7,754	7,977
Total operating expenses	29,806	29,152
Income (Loss) from operations	11,657	(5,653)
Interest income	2,194	2,327
Other (expense) income, net	(11)	15
Income (Loss) before income taxes	13,840	(3,311)
Provision for income taxes	49	0
Net Income (loss)	13,791	(3,311)
Other comprehensive income (loss):
Unrealized (loss) gain on investments, net of tax	(105)	16
Total comprehensive income (loss)	$ 13,686	$ (3,295)
Net income (loss) per share, Basic	$ 0.17	$ (0.05)
Net income (loss) per share, Diluted	$ 0.17	$ (0.05)
Shares used to compute net income (loss) per share, Basic	82,029,466	66,248,992
Shares used to compute net income (loss) per share, Diluted	82,630,020	66,248,992

CTMX Balance Sheet

2024-03-31

CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands

Mar. 31, 2024

Dec. 31, 2023

^[1]

Mar. 31, 2023

Dec. 31, 2022

Current assets:

Cash and cash equivalents

$ 36,185

$ 17,171

Short-term investments

114,099

157,338

Accounts receivable

13,177

3,432

Prepaid expenses and other current assets

3,786

4,995

Total current assets

167,247

182,936

Property and equipment, net

3,567

3,958

Intangible assets, net

693

729

Goodwill

949

Restricted cash

917

Operating lease right-of-use asset

11,234

12,220

Other assets

80

83

Total assets

184,687

201,792

Current liabilities:

Accounts payable

1,964

1,458

Accrued liabilities

14,220

17,599

Operating lease liabilities - short term

4,724

4,589

Deferred revenue, current portion

123,628

132,267

Total current liabilities

144,536

155,913

Deferred revenue, net of current portion

59,743

80,048

Operating lease liabilities - long term

8,148

9,385

Other long-term liabilities

3,940

3,893

Total liabilities

216,367

249,239

Commitments and contingencies (Note 9)

Stockholders' deficit:

Convertible preferred stock

0

Common stock

1

Additional paid-in capital

677,986

675,905

Accumulated other comprehensive (loss) income

(10)

95

Accumulated deficit

(709,657)

(723,448)

Total stockholders' deficit

(31,680)

(47,447)

$ (86,637)

$ (85,751)

Total liabilities and stockholders' deficit

$ 184,687

$ 201,792

[1]	The condensed balance sheet as of December 31, 2023 was derived from the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.

About CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; CX-2051, a conditionally activated ADC that targets epithelial cell adhesion molecule-expressing epithelial cancers; and CX-801, a dually masked, conditionally activated version of Interferon alpha-2b therapy for a range of tumor types. The company also develops BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I/II clinical trials for the treatment of solid tumors; and CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. It has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, Astellas Pharma Inc., ModernaTX, Inc., and Regeneron Pharmaceuticals, Inc. The company was founded in 2008 and is headquartered in South San Francisco, California.

CEO	Dr. Sean A. McCarthy D.Phil., DPHIL
WEBSITE	cytomx.com
INDUSTRY	Biotechnology
EMPLOYEES	116

CytomX Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for CytomX Therapeutics Inc? What does CTMX stand for in stocks?

CTMX is the stock ticker symbol of CytomX Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CytomX Therapeutics Inc (CTMX)?

As of Fri May 17 2024, market cap of CytomX Therapeutics Inc is 127.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CTMX stock?

You can check CTMX's fair value in chart for subscribers.

What is the fair value of CTMX stock?

You can check CTMX's fair value in chart for subscribers. The fair value of CytomX Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CytomX Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CTMX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CytomX Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CTMX is over valued or under valued. Whether CytomX Therapeutics Inc is cheap or expensive depends on the assumptions which impact CytomX Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CTMX.

What is CytomX Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, CTMX's PE ratio (Price to Earnings) is 7.74 and Price to Sales (PS) ratio is 1.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CTMX PE ratio will change depending on the future growth rate expectations of investors.